We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A new non-invasive test that uses blood samples to diagnose cases of colorectal cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The test developed by researchers at the Medical Research Institute (Alexandria, Egypt) could facilitate screening efforts for colorectal cancer. Colorectal cancer is one of the leading causes of death from cancer worldwide, and detecting the disease early is essential for a good prognosis. Although colonoscopies are the most effective tools for diagnosis, many patients avoid getting them due to their invasive nature. Other tests such as those for occult blood in stool are less invasive, but don’t have the same accuracy and performance, and can yield false positives that lead to unnecessary follow-up colonoscopies for patients.

The new non-invasive blood test may help identify cases of colorectal cancer and improve patient compliance with screening. Using multiplex bead technology, the researchers examined levels of the inflammatory proteins eotaxin-1, MIP-1 beta, G-CSF, VEGF-A, and Fas ligand in 35 patients with colorectal cancer and 52 individuals without cancer. The first four proteins were elevated in the cancer patients, suggesting these proteins could serve as potential biomarkers for future screening efforts. The researchers also found that the multiplex bead test outperformed routine stool occult blood tests.

“The main novel aspect of our study is the use of multiplex technology in simultaneous measuring of serum-based biomarkers in [colorectal cancer] diagnosis, which will reduce cost and time,” said Dr. Mona Eldeeb of the Medical Research Institute who led the team. “The overall performance of the studied serum biomarkers is much better than routinely used occult blood in screening [colorectal cancer].”

Related Links:
Medical Research Institute 

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Hematology Analyzer
BH-6180
New
Gastrointestinal Infection Test
REALQUALITY ETEC/EIEC

Print article
ADLM

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.